Media coverage about Joint (NASDAQ:JYNT) has been trending somewhat positive on Thursday, Accern Sentiment reports. The research group identifies negative and positive media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Joint earned a media sentiment score of 0.23 on Accern’s scale. Accern also gave media coverage about the company an impact score of 48.2290633919857 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Several equities analysts recently issued reports on the company. Zacks Investment Research upgraded Joint from a “hold” rating to a “buy” rating and set a $9.75 price target on the stock in a report on Wednesday, August 15th. Roth Capital restated a “buy” rating on shares of Joint in a report on Friday, August 10th. ValuEngine downgraded Joint from a “strong-buy” rating to a “buy” rating in a report on Monday, July 2nd. Finally, Maxim Group restated a “buy” rating and set a $10.00 price target on shares of Joint in a report on Friday, May 11th. Five analysts have rated the stock with a buy rating, The company currently has an average rating of “Buy” and an average target price of $10.58.
NASDAQ JYNT remained flat at $$8.75 during trading hours on Thursday. The company’s stock had a trading volume of 13,900 shares, compared to its average volume of 60,673. The company has a current ratio of 1.30, a quick ratio of 1.30 and a debt-to-equity ratio of 0.75. Joint has a 12 month low of $4.10 and a 12 month high of $9.64. The stock has a market cap of $117.63 million, a P/E ratio of -35.00 and a beta of 0.90.
Joint (NASDAQ:JYNT) last issued its quarterly earnings results on Thursday, August 9th. The company reported $0.01 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.01) by $0.02. Joint had a negative return on equity of 34.99% and a negative net margin of 3.72%. The company had revenue of $7.56 million for the quarter, compared to the consensus estimate of $7.62 million. analysts anticipate that Joint will post 0.06 EPS for the current year.
In related news, Director James H. Amos, Jr. purchased 10,000 shares of the business’s stock in a transaction on Thursday, August 23rd. The shares were bought at an average price of $8.74 per share, for a total transaction of $87,400.00. Following the acquisition, the director now directly owns 72,797 shares in the company, valued at $636,245.78. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO John P. Meloun sold 40,539 shares of the company’s stock in a transaction dated Thursday, June 28th. The stock was sold at an average price of $8.01, for a total value of $324,717.39. Following the sale, the chief financial officer now owns 18,922 shares in the company, valued at approximately $151,565.22. The disclosure for this sale can be found here. 3.20% of the stock is owned by corporate insiders.
The Joint Corp. develops, owns, operates, supports, and manages chiropractic clinics in the United States. It operates through direct ownership, management arrangements, franchising, and the sale of regional developer rights. As of August 9, 2018, the company operated approximately 400 clinics. The company was founded in 2010 and is headquartered in Scottsdale, Arizona.
Featured Article: What is a Stop Order?
Receive News & Ratings for Joint Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Joint and related companies with MarketBeat.com's FREE daily email newsletter.